Table 5.
Anti-HER2 targeted antibody trials for breast cancer in the recruitment phase
Agent | Trial / Phase | Setting |
---|---|---|
Margetuximab | A Study to Evaluate the Efficacy and Safety of Margetuximab plus Chemotherapy in the Treatment of Chinese Patients with HER2+ MBC / Phase 2 | Metastatic |
A Study of MGD013 in Patients with Unresectable or Metastatic Neoplasms / Phase 1 | Metastatic |